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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Large total prostate volumes (TPVs) or high serum prostate-specific an-
tigen (PSA) levels indicate high-risk clinical progression of benign prostatic hyperplasia. This
prospective study investigated the treatment outcome of combined 5a-reductase inhibitor
and a-blocker in patients with and without large TPVs or high PSA levels.
Methods: Men aged  45 years with International Prostate Symptom scores (IPSS)  8, TPV 
20mL, andmaximum flow rate 15mL/s received a combination therapy (dutasteride plus dox-
aben) for 2 years. Patients with baseline PSA  4 ng/mL underwent prostatic biopsy for
excluding malignancy. The changes in the parameters from baseline to 24 months after combi-
nation therapy were compared in those with andwithout TPV 40mL or PSA levels 1.5 ng/mL.
Results: A total of 285 patients (mean age 72 9 years) completed the study. Combination ther-
apy resulted in significant continuous improvement in IPSS, quality of life index, maximum flow
rate, and postvoid residual (all p < 0.0001) regardless of baseline TPV or PSA levels. However,
only patients with baseline TPV 40 mL had significant improvements in IPSS-storage subscore,
voided volume, reduction in TPV, transitional zone index, and PSA levels. In addition, patients
with baseline TPV< 40 mL and PSA< 1.5 ng/mL had neither a reduction in TPV nor a decrease in
serum PSA level.ave no conflicts of interest relevant to this article.
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866 V.C. Lin et al.Conclusion: A high TPV indicates more outlet resistance, whereas elevated serum PSA level re-
flects glandular proliferation. Thus, patients with TPV<40 mL and low PSA levels has less benefit
from 5a-reductase inhibitor therapy. The therapeutic effect of combined treatment may arise
mainly from the a-blocker in these patients.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction stroke, spinal cord injury, Parkinson’s disease, or otherBenign prostatic hyperplasia (BPH) with lower urinary tract
symptoms (LUTS) is a progressive disease.1e5 With the
introduction of selective a-blockers and 5a-reductase in-
hibitors (5ARI) in the 1990s, the natural history of BPH/LUTS
has changed.3,4 The Medical Therapy of Prostate Symptoms
(MTOPS) and Combined Therapy of Avodart and Tamsulosin
(CombAT) studies have assessed the long-term outcomes of
combination therapy (a-blocker plus 5ARI)6e8 and suggest
that a-blockers cannot reduce the risk of progression
without additional treatment with 5ARI. Furthermore,
compared with monotherapy, combination therapy signifi-
cantly improves LUTS symptoms.6e8
Compared with the patients in the MTOPS, the CombAT
study enrolled BPH/LUTS patients with large total prostate
volumes (TPVs, 30 mL vs. 25 mL) and/or higher prostatic
specific antigen (PSA) levels (> 1.5 ng/mL). The results
indicate that 5ARI may play a role in patients with a risk of
disease progression. However, the prostatic size that cau-
ses BPH/LUTS might be different between Western and
Asian men.9,10 The effectiveness of combined 5ARI and a-
blocker on patients with different prostate size or PSA level
remains unknown, especially in the Asian population.
Our aim was to investigate further the therapeutic ef-
fect of combination therapy in patients with different
prostate size and PSA level. Current European Association
of Urology (EAU) guidelines suggest 5ARI should be offered
to men who have moderate-to-severe lower urinary tract
symptoms and enlarged prostates (> 40 mL) or elevated
prostate specific antigen concentrations (> 1.4e1.6 mg/
L).11 We conducted the current prospective multicenter
study in the Taiwanese population to compare the treat-
ment outcome of combined 5ARI and a-blocker in patients
with and without TPV  40 mL or PSA  1.5 ng/mL.
Materials and methods
Study inclusion and exclusion criteria
Male patients aged  45 years in Taiwan with a clinical
diagnosis of BPH were included. The patients also fulfilled
the following criteria: moderate-to-severe LUTS with an
International Prostate Symptoms score (IPSS)  8, TPV 
20 mL by transrectal ultrasonography of the prostate
(TRUS-P), maximum flow rate (Qmax)  15 mL/s with
minimal voided volume  125 mL, and serum PSA
level < 4 ng/mL. We chose TPV > 20 mL as inclusion cri-
terion based on the regulation by the National Health In-
surance in Taiwan. If serum PSA was  4 ng/mL, TRUS-P-
guided biopsy was performed to exclude the presence of
prostate cancer prior to initiating 5ARI therapy.
The exclusion criteria were men with: TPV < 20 mL;
evidence of prostate cancer; neurogenic bladder due tosevere neurologic disease; contraindication to performing
digital rectal examination or TRUS-P; urinary tract infection
or urinary retention within 3 months prior to the study; or
receiving any 5ARI, anti-androgen, or phytotherapy treat-
ment 6 months prior to the study.
Study design
This study was a prospective, multicenter, open-label,
observational study in men with symptomatic BPH. All
eligible patients received dutasteride 0.5 mg once daily
with concomitant a-blocker therapy (doxazosin 4 mg per
day) for a 2-year period. If patients had postural hypoten-
sion after doxazosin treatment, other a-blocker such as
tamsulosin (0.2e0.4 mg/day) was used. The self-
administered IPSS questionnaire was implemented at
baseline, and then repeated every 6 months for 2 years.
Uroflowmetry analysis was performed, and voiding vol-
umes, PVR volumes, and serum PSA levels were measured
during each visit, whereas TRUS-P was performed to mea-
sure prostate volume parameters, including total prostate
volume (TPV) and transitional zone index (TZI).
Study endpoint
An expert review of published evidence regarding BPH as a
progressive disease defined progression as worsening of
symptoms, deterioration of urinary flow rate, increase in
TPV, and outcomes such as acute urinary retention (AUR)
and the need for surgery either for AUR or symptoms.12 In
the MTOP study, the definition of clinical progression was
an increase in IPSS of  4 points, AUR, urinary inconti-
nence, renal insufficiency, or recurrent urinary tract
infection.6 We added more clear criteria of decreased
Qmax and increased PVR in our study. For the preplanned
analysis at 2 years, the primary endpoint was the net
change in IPSS, uroflowmetric and prostate parameters,
and serum PSA level from baseline to 24 months after the
first treatment day. The secondary endpoint was com-
parison of the treatment outcome between patients with
and without TPV  40 mL or PSA  1.5 ng/mL. The
occurrence of clinical BPH progression was defined as IPSS
increased by  4 points, Qmax decreased by  2 mL/s,
and PVR urine volume increased by  150 mL compared
with baseline values, episodes of acute urinary tract
infection, episodes of acute urinary retention (AUR), or
the need for BPH-related surgery during the treatment
period.
Statistical analysis
For all analyses, the variables are presented as the
mean  standard deviation, number, or percentage.
5ARI is less effective in men with small prostates 867Continuous data in two groups were evaluated by Man-
neWhitney U tests to compare the means. Multiple mea-
surement analysis was used to evaluate the significant
difference of variables between groups with time points.
Categorical data were analyzed using the Chi-square test
with Fisher’s exact probability test, as appropriate. A p
value < 0.05 was considered statistically significant. The
statistics program used for the analysis was SPSS version
17.0 (SPSS Inc., Chicago, IL, USA) for Windows.
Results
Patient demographics
A total of 285 patients completed the study up to the 2-year
follow-up. The mean age was 72  9 years (range, 45e92
years). There were 150 (52.6%) patients with baseline TPV
 40 mL and 135 (47.4%) patients with TPV < 40 mL,
whereas there were 158 (55.4%) individuals with baseline
PSA levels  1.5 ng/mL and 127 (44.6%) individuals with PSA
levels < 1.5 ng/mL.Table 1 Changes in IPSS, QoL index, prostate, and uroflow para
volume (TPV)  40 mL (n Z 150) or < 40 mL (n Z 135).
Baseline 6 mo 12 m
IPSS-V
TPV  40 mL 8.64  5.64 4.64  4.48 4.35
TPV < 40 mL 7.96  5.10 4.49  4.48 3.19
IPSS-S
TPV  40 mL 6.89  3.70 5.08  3.02 4.59
TPV < 40 mL 5.87  3.18 4.39  2.58 4.19
IPSS-T
TPV  40 mL 15.5  7.40 9.72  6.24 8.94
TPV < 40 mL 13.8  6.64 8.87  5.67 7.39
QoL index
TPV  40 mL 3.68  1.24 2.55  1.00 2.30
TPV < 40 mL 3.41  1.20 2.45  1.03 2.21
Qmax
TPV  40 mL 9.92  5.23 11.4  5.45 11.6
TPV < 40 mL 10.7  5.28 11.7  6.00 11.9
Void volume
TPV  40 mL 164  93.6 197  111 208
TPV < 40 mL 214  128 231  137 226
PVR
TPV  40 mL 67.8  64.3 64.5  56.7 57.2
TPV < 40 mL 79.9  76.1 61.9  61.3 54.5
TPV
TPV  40 mL 60.8  21.4 51.6  20.9 50.1
TPV < 40 mL 29.3  6.03 26.0  7.58 26.6
TZI
TPV  40 mL 0.52  0.13 0.49  0.13 0.49
TPV < 40 mL 0.41  0.14 0.41  0.14 0.38
PSA
TPV  40 mL 3.88  4.02 2.71  2.84 2.27
TPV < 40 mL 2.06  2.79 1.40  1.59 1.48
IPSSZ International Prostatic Symptom score; PSAZ prostatic specifi
QoL Z quality of life; S Z storage; TZI Z transition zone index; V ZChanges in IPSS, uroflow, and prostate parameters
with time in the overall patient group
From baseline to 24 months, the combination therapy
resulted in a significantly continuous improvement in IPSS
and quality of life (QoL) index (p < 0.001) in the overall
patient group. When total IPSS (IPSS-T) was categorized as
storage subscore (IPSS-S) and voiding subscore (IPSS-V), all
three IPSS groups showed continuous improvement with
time (p < 0.001). The Qmax and voided volume increased
significantly from baseline to 6 months and remained
improved up to 24 months. PVR volume showed continuous
improvement with time, whereas TPV, TZI, and PSA all
showed significant decreases from baseline to 6 months,
and steadily improved up to 24 months (all p < 0.001).
Changes in IPSS, uroflow, and prostate parameters
by baseline TPV ‡ 40 mL or< 40 mL
Combination therapy resulted in significant and continuous
improvement in IPSS-T, IPSS-S, IPSS-V, and QoL index in themeters and PVR urine volume from the baseline total prostate
o 18 mo 24 mo p
 4.00 3.16  3.59 3.15  3.93 0.316
 3.85 3.24  3.83 3.10  3.76
 2.64 4.29  2.54 3.75  2.25 0.050
 2.53 4.06  2.31 3.66  2.22
 5.45 7.45  5.22 6.90  5.33 0.098
 5.30 7.30  5.07 6.76  4.89
 0.89 2.19  0.79 2.11  0.80 0.275
 0.91 2.19  0.80 2.15  0.77
 5.15 12.9  5.95 12.7  5.51 0.890
 5.60 12.2  5.23 12.4  6.15
 108 227  125 231  138 0.015
 134 252  139 252  158
 53.3 60.4  53.6 57.4  53.1 0.536
 56.3 60.6  60.3 65.0  70.6
 22.1 48.1  21.5 48.9  21.1 < 0.001
 8.20 28.2  22.7 28.0  20.8
 0.13 0.48  0.13 0.45  0.12 < 0.001
 0.13 0.37  0.13 0.37  0.13
 2.20 2.23  2.11 2.29  2.19 < 0.001
 1.88 1.50  2.00 1.53  2.02
c antigen; PVRZ postvoid residual; QmaxZ maximum flow rate;
voiding.
868 V.C. Lin et al.subgroup of patients with baseline TPV  40 mL or < 40 mL
(all p < 0.001). There was no significant difference in
changes in IPSS-T, IPSS-V, and QoL indices between the two
subgroups with time, but IPSS-S was significantly improved
only in the group of patients with TPV  40 mL (Table 1).
Changes in uroflow parameters and PVR urine volume also
showed no significant difference between subgroups with
TPV  40 mL or < 40 mL, except that voiding volume was
significantly increased in patients with TPV  40 mL. Pa-
tients with TPV  40 mL showed significantly greater
reduction of TPV and PSA values from baseline to 24 months
than patients with TPV < 40 mL, whereas TZI showed no
difference in reduction.
Changes in IPSS, uroflow, and prostate parameters
by baseline PSA ‡ 1.5 ng/mL or< 1.5 ng/mL
From baseline to 24 months, combination treatment resulted
in significant and continuous improvement in IPSS-T, IPSS-S,
IPSS-V, and QoL index regardless of baseline PSA  1.5 or
<1.5 ng/mL (all p < 0.0001). Uroflow parameters, including
Qmax, voided volume, and PVR urine volume, also showed
significantly continuous improvement (p < 0.0001), but
there was no difference between the two subgroups. Pros-
tate parameters, including TPV, TZI, and PSA, all showed
significantly greater reduction in the subgroup with baseline
PSA  1.5 ng/mL than those with PSA < 1.5 ng/mL (Table 2).
Changes in IPSS, uroflow, and prostate parameters
by different baseline TPV and PSA levels
If the patients were divided into subgroups according to
baseline TPV  40 or TPV < 40 mL and PSA levels  1.5 or
PSA levels < 1.5 ng/mL, there was no significant difference
among the four subgroups in all IPSS, QoL index, uro-
flowmetric parameters, and PVR urine volume from base-
line to 24 months after combination treatment. However,
TPV showed significantly greater reduction in subgroups
with baseline TPV  40 mL regardless of baseline PSA level.
PSA also showed significantly greater reduction in sub-
groups with baseline PSA levels  1.5 ng/mL regardless of
baseline TPV. Patients with baseline TPV < 40 mL and PSA
levels < 1.5 ng/mL had neither reduction of TPV nor
decrease of serum PSA levels (Table 3).
Changes in IPSS, uroflow, and prostate parameters
by reduction of TPV by ‡ 20% or< 20% of baseline
values
Changes in IPSS, QoL index, uroflow, and prostate parameters
in subgroups with TPV reduction of  20% or < 20% from
baseline values are shown in Table 4. There was no significant
difference between the two groups. Patients without TPV
reduction 20% fared aswell as thosewithTPVreduction of
20% after combined dutasteride and a-blocker treatment.
Progression of BPH during the treatment period
During the treatment period, BPH progression was reported
in 13 patients with an increase in IPSS by  4 points and inseven with PVR urine volume increase of  150 mL
compared with baseline values. Four patients had episodes
of AUR. Among those with BPH progression, there were no
significant differences in incidence between patients with
baseline TPV  40 mL or < 40 mL. In addition, BPH-related
surgery was performed only in six patients: all had a
baseline TPV  40 mL, but this was not associated with
baseline PSA level.Discussion
PH is a progressive disease.1e5 As prostate volume or PSA
increases, it is evident that the possibility of symptom
deterioration and risk of AUR and need for BPH-related
surgery increase.4,13,14 In men with BPH and moderate-to-
severe LUTS, the therapeutic benefits of finasteride were
observed in the Proscar long-term efficacy and safety
study.15 Finasteride treatment significantly improved IPSS
and reduced TPV, with significantly reduced relative risk of
AUR and BPH-related surgery in men receiving finasteride
versus placebo (p < 0.001). The MTOPS study provided
valuable information for the combination therapy as the
most effective treatment regarding reducing the overall
risk of progression and improving LUTS in BPH patients.6
Recently, the 4-year CombAT study further demon-
strated that the combination of dutasteride and tamsulosin
was more effective than either monotherapy in reducing
the overall progression in men with BPH and moderate-to-
severe LUTS. Furthermore, the CombAT study included
patients who were at increased risk of progression by virtue
of having larger prostate volume and higher PSA level (TPV
 30 mL, PSA  1.5 ng/mL).7,8
The MTOPS and CombAT studies have provided valuable
information on using risk factors to identify patients whose
BPH is likely to progress, and the benefits of using 5ARI to
prevent progression in high-risk patients. Thus, the new
drug 5ARI could transform BPH from a surgical disease to a
medically controllable one. However, current guidelines
often lack recommendations on how to choose appropriate
treatments for individual needs. Knowledge of the appli-
cation of modern drug treatments such as combination
therapy to appropriate patients is essential because of the
financial burden in some countries, such as those with a
fixed budget policy for healthcare. Emberton et al13 pro-
posed a practical BPH treatment allocation by risk stratifi-
cation. In men with BPH, combination therapy is
recommended in patients with moderate-to-severe LUTS in
the presence of TPV > 30 mL or PSA levels > 1.4 ng/
mL.8,13,14
Although TPV > 30 mL was proposed as a cutoff value for
selecting patients with LUTS for combined 5ARI and a-
blocker therapy, whether men with BPH and TPV < 40 mL
also benefit from combination therapy has not been
demonstrated. The mechanism of action of 5ARI is sup-
posedly to reduce the prostatic volume; therefore, the TPV
and PSA levels should be reduced after 5ARI therapy for
more than 1 year. If a patient’s TPV and PSA are not
reduced after 5ARI therapy, the therapeutic effect of
combination therapy might be solely due to the effect of
the a-blocker. Adding 5ARI to the a-blocker for treatment
of BPH/LUTS is unnecessary.
Table 2 Changes in IPSS, QoL index, prostate and uroflow parameters, and PVR urine volume by baseline PSA level.
Baseline 6 mo 12 mo 18 mo 24 mo p
IPSS-V
PSA  1.5 8.35  5.64 4.38  4.39 4.08  4.10 3.01  3.45 2.72  3.82 0.376
PSA < 1.5 8.27  5.09 4.80  4.58 3.46  3.78 3.43  3.99 2.65  3.82
IPSS-S
PSA  1.5 6.37  3.58 4.65  2.88 4.49  2.63 4.20  2.53 3.61  2.29 0.890
PSA < 1.5 6.44  3.40 4.87  2.80 4.29  2.55 4.16  2.31 3.83  2.16
IPSS-T
PSA  1.5 14.7  7.45 9.03  6.17 8.57  5.59 7.21  5.09 6.32  5.15 0.473
PSA < 1.5 14.7  6.64 9.68  5.74 7.75  5.20 7.59  5.21 7.47  5.03
QoL index
PSA  1.5 3.55  1.27 2.46  1.03 2.25  0.91 2.13  0.78 2.05  7.08 0.156
PSA < 1.5 3.55  1.17 2.56  1.01 2.27  0.87 2.25  0.81 2.22  0.78
Qmax
PSA  1.5 10.4  5.81 11.4  6.00 11.8  5.82 12.7  6.23 13.0  6.35 0.633
PSA < 1.5 10.2  4.49 11.7  5.30 11.6  4.76 12.4  4.77 12.0  5.05
Void volume
PSA  1.5 181  110 201  113 213  119 229  133 238  146 0.487
PSA < 1.5 196  119 229  137 220  124 251  131 245  151
PVR
PSA  1.5 77.5  72.7 67.4  63.5 59.4  55.7 63.7  61.6 63.2  63.1 0.219
PSA < 1.5 68.7  67.0 58.1  52.3 51.5  53.1 56.5  50.1 58.3  60.8
TPV
PSA  1.5 54.2  24.3 46.0  21.5 45.6  22.8 44.0  22.4 44.4  21.5 0.983
PSA < 1.5 35.5  14.5 31.2  15.7 30.8  13.8 32.2  24.8 32.3  23.8
TZI
PSA  1.5 0.50  0.14 0.47  0.14 0.46  0.14 0.46  0.13 0.44  0.14 0.067
PSA < 1.5 0.42  0.15 0.42  0.14 0.41  0.14 0.40  0.14 0.38  0.13
PSA
PSA  1.5 4.76  4.07 3.08  2.80 2.72  2.39 2.72  2.39 2.73  2.43 0.381
PSA < 1.5 0.85  0.36 0.85  0.82 0.87  0.91 0.84  0.84 0.94  1.08
PSA  1.5 ng/mL: n Z 158; PSA < 1.5 ng/mL: n Z 127.
IPSSZ International Prostatic Symptom score; PSAZ prostatic specific antigen; PVRZ postvoid residual; QmaxZ maximum flow rate;
QoL Z quality of life; S Z storage; TPV Z total prostatic volume; TZI Z transition zone index; V Z voiding.
5ARI is less effective in men with small prostates 869The current post hoc analysis of a 2-year prospective,
multicenter study in Taiwan provides alternative insights
into the effect of dutasteride in symptomatic BPH patients
with different prostate size and PSA levels. Like theTable 3 Changes in IPSS, QoL index, prostate, and uroflow par
among the subgroups with different baseline TPV and PSA levels.
TPV  40, PSA  1.5
(n Z 110)
TPV > 40, PSA  1.5
(n Z 48)
DIPSS-V 5.72  6.23 5.46  5.38
DIPSS-S 3.03  3.61 2.17  3.32
DIPSS-T 8.75  7.92 7.63  6.78
DQoL index 1.57  13.9 1.33  1.36
DQmax 2.69  5.88 2.43  6.94
DVolume 66.2  134 36.0  138
DPVR 9.43  84.6 25.6  100
DTPV 12.2  17.0 4.33  8.91
DTZI 0.07  0.16 0.05  0.18
DPSA 2.20  3.22 1.63  2.03
IPSSZ International Prostatic Symptom score; PSAZ prostatic specifi
QoL Z quality of life; S Z storage; TPV Z total prostatic volume; TZCombAT study, dutasteride treatment resulted in significant
improvements in IPSS, QoL index, and uroflowmetric pa-
rameters at 24 months regardless of baseline TPV or PSA
level. However, only patients with baseline greater TPVameters, and PVR urine volume from baseline to 24 months
TPV  40, PSA < 1.5
(n Z 40)
TPV < 40, PSA < 1.5
(n Z 87)
p
4.89  6.16 4.52  5.02 0.500
3.45  3.78 2.23  3.16 0.134
8.30  7.87 6.75  6.81 0.295
1.58  1.24 1.22  1.32 0.251
2.92  6.31 1.30  4.52 0.312
70.4  143 39.2  139 0.355
13.0  61.2 9.12  90.5 0.713
11.0  10.9 0.36  24.4 < 0.001
0.07  0.10 0.03  0.16 0.393
0.11  1.50 0.07  0.82 < 0.001
c antigen; PVRZ postvoid residual; QmaxZ maximum flow rate;
I Z transition zone index; V Z voiding.
Table 4 Changes in IPSS, QoL index, prostate, and uroflow
parameters and PVR from baseline to 24 months among
subgroups with TPV reduction  20% or < 20% of baseline
values.
TPV reduction 
20% (n Z 130)
TPV reduction
< 20% (n Z 155)
p
DIPSS-V 5.15  5.74 5.22  5.74 0.915
DIPSS-S 2.74  3.51 2.66  3.45 0.858
DIPSS-T 7.88  7.54 7.88  7.33 0.999
DQoL index 1.32  1.41 1.52  1.28 0.210
DQmax (mL/s) 2.46  5.62 2.09  5.90 0.592
DVolume (mL) 50.7  147 55.8  129 0.757
DPVR (mL) 19.6  87.6 6.67  84.9 0.209
DTPV (mL) 17.2  11.3 1.80  19.4 < 0.001
DTZI 0.04  0.15 0.06  0.16 0.232
DPSA (ng/mL) 1.37  2.85 0.85  2.18 0.085
IPSSZ International Prostatic Symptom score; PSAZ prostatic
specific antigen; PVR Z postvoid residual; Qmax Z maximum
flow rate; QoL Z quality of life; S Z storage; TPV Z total
prostatic volume; TZI Z transition zone index; V Z voiding.
870 V.C. Lin et al.( 40 mL) or higher PSA ( 1.5 ng/mL) had any significant
reduction in TPV or PSA level. Patients with TPV < 40 mL
but PSA  1.5 ng/mL had a mild reduction in TPV, but pa-
tients with TPV < 40 mL and PSA < 1.5 ng/mL did not
reduce TPV or PSA at all.
A large TPV usually indicates more outlet resistance,
while elevated serum PSA level could be a reflection of
glandular proliferation. Eckhardt et al16 found a positive
correlation between prostate volume and Scha¨fer’s
obstruction grade. The degree of bladder outlet obstruc-
tion defined by the increment in the Abrams-Griffiths
number was also significantly correlated with TPV as
measured by TRUS-P.17 This result indicates that the ef-
fect of 5ARI (dutasteride) on prostatic hyperplasia is
clearly demonstrated in patients with larger TPV and
higher PSA. Because the TPV did not change after com-
bination therapy, the therapeutic effect of combination
therapy on those with small BPH and PSA levels < 1.5 ng/
mL is likely to be due to the a-blocker, and 5ARI does not
appear to contribute to the improvement of IPSS or uro-
flow parameters.
This study also shows that improvements in IPSS, QoL
index, and uroflow parameters are not associated with TPV
reduction following combined 5ARI and a-blocker treat-
ment. Patients with a TPV reduction < 20% have the same
treatment outcome as those with reduction  20% of
baseline TPV. Although TPV and PSA reduction seems
greater in patients with greater BPH, patients without TPV
reduction also have similar improvements in IPSS and uro-
flow parameters. The therapeutic effect of a-blockers
might be greater in patients with small BPH and little
reduction in TPV. However, patients with a large TPV at
baseline are more likely to progress and BPH-related sur-
gery is needed during long-term combination therapy.
Therefore, the true therapeutic effect of 5ARI involves the
reduction of prostate volume and application of a safety
valve for long-term medical treatment on large BPH.A high PSA level may be due to large TPV, chronic
inflammation, or occult prostate cancer. Recently, chronic
inflammation in the prostate has been considered to play an
important role in the development of LUTS in patients with
BPH.18,19 Patients with high serum C-reactive protein (CRP)
levels and BPH are associated with higher storage LUTS,
implying a possible link between chronic inflammation and
sensory nerves in the lower urinary tract.20,21 The present
study shows that combined dutasteride and a-blocker
treatment effectively results in significant improvement in
IPSS storage subscores and voiding volume in patients with
TPV  40 mL compared with TPV < 40 mL. This finding
implies that the therapeutic effect of 5ARI may lie beyond
reduction in prostatic volume or bladder outlet obstruction.
Reduction in TPV is associated with a reduction in PSA: not
only is prostatic hyperplasia inhibited, but chronic inflam-
mation can also be reduced after 2 years of 5ARI therapy.
Last, data from a subgroup analysis of MTOPS suggested
that the presence of prostatic inflammation may indicate a
greater likelihood of treatment efficacy with a combination
of a-blockers and 5ARI therapy.22 Although our results did
not show a greater effect on IPSS and uroflow parameters
for patients with TPV  40 mL compared with those with
TPV < 40 mL, reductions and PSA and a better improvement
in storage IPSS subscore and voiding volume were noted
only in the TPV  40 mL group, suggesting that 5ARI therapy
is suitable only for patients with a larger BPH.
There are some inherent limitations in this study. First,
we could not perform experiments using a placebo arm as
controls because of ethical reasons. Second, we performed
only baseline prostate biopsy for patients with high PSA
levels but did not perform protocol biopsy of the prostate,
except when the possibility of prostate cancer arose.
However, the study findings may reflect the real world
practice in Asian men with clinical BPH.
In conclusion, a high TPV indicates more outlet resis-
tance, whereas elevated serum PSA level reflects glandular
proliferation. Thus, patients with TPV < 40 mL and low PSA
levels have less benefit from 5ARI therapy. The therapeutic
effect of combined treatment may arise mainly from the a-
blocker in these patients.References
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